

JDI Journal of Diabetes Investigation

Official journal of the Asian Association for the Study of Diabetes

AUTHOR GUIDE

Thank you for your interest in the *Journal of Diabetes Investigation*. Please take a moment to consult the following instructions to help you prepare your manuscript, and feel free to contact us with any questions. To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.

CONTENTS

1. About the Journal
2. Peer Review
3. Manuscript Categories
4. Disclosure
5. Ethical Considerations
6. Clinical Trials Registry
7. Randomized Controlled Trials
8. Copyright
9. Style of Manuscripts
10. Structure of Manuscripts
11. Supporting Information
12. Submission of Manuscripts
13. Proofs
14. Offprints
15. Color and Page Fees
16. Tracking Manuscripts
17. Online Open
18. EarlyView
19. The Journal Online
20. Editorial Office

1. ABOUT THE JOURNAL

Scope *Journal of Diabetes Investigation* is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes a variety of original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. The journal embraces clinical and experimental research in diabetes and related areas. This includes aspects of prevention, treatment, education, nutrition, metabolic risk, psychosocial and socio-economic research, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcomed. Authors and readers from all countries are welcome, and are provided with an international editorial team of experts from AASD countries and beyond.

Editor Nigishi Hotta

Frequency 6 issues per year

ISSN 2040-1116 (print); 2040-1124 (online)

Journal abbreviation J Diabetes Invest

Publisher Wiley-Blackwell, an imprint of John Wiley & Sons, Inc

2. EDITORIAL REVIEW AND ACCEPTANCE

Before peer review: Your contribution must be your own original work, which will contribute to the progress of diabetes research and treatment, and must not have been published elsewhere. Your contribution must be accompanied by your signed copyright form, a statement that your contribution has not been published elsewhere, and is not being peer reviewed elsewhere.

Acceptance: The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers, an Associate Editor and the Editor. The Editorial Board reserves the right to refuse material for publication. Final accep-

tance or rejection rests with the Editorial Board.

Authors may present names of potential reviewers and of reviewers whom they would prefer not to review the manuscript in a covering letter. The selection of reviewers remains the Editor's prerogative.

All manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. They should be written in a clear, concise, direct style. Where contributions are judged as acceptable for publication, the Editor and the Publisher reserve the right to modify manuscripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

3. MANUSCRIPT CATEGORIES

(1) ORIGINAL ARTICLE

Word limit: 4,000 words including title page, abstract but excluding references, tables and figures.

Abstract: 250 words maximum, structured (sub-headers): Aims/Introduction, Materials and Methods, Results, Conclusions.

References: No limit.

Description: Full-length reports of current research in either basic or clinical science. Arrange text as follows: Abstract; Introduction; Materials and Methods; Results; Discussion; Acknowledgment; References; and when relevant Supporting Information. Video is welcome as Supporting Information.

(2) SHORT REPORT

Word limit: 1,500 words including title page, abstract but excluding references, tables and figures.

Abstract: 150 words maximum, unstructured (no use of sub-headers).

References: Maximum 30.

Figures/tables: Maximum 4.

Description: New findings that will substantial-

ly and immediately affect research or clinical practice. Arrange text as follows: Abstract; Introduction; Materials and Methods; Results; Discussion; Acknowledgment; References; and when relevant Supporting Information. Video is welcome as Supporting Information.

(3) CASE REPORT

Only cases of exceptional interest and novelty are considered. For manuscripts that do not qualify, Editors may ask authors to shorten manuscripts and rewrite as Letters to the Editor.

Word limit: 1,200 words including title page, abstract but excluding references, tables and figures. The total should be within 2 typeset pages including tables and figures.

Abstract: 150 words maximum, unstructured (no use of sub-headers).

References: Maximum 10.

Figures/tables: Maximum 4 (1a, 1b, 1c are counted as 3 figures not 1 figure).

Description: New observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners. Arrange text as follows: Abstract; Introduction; Case Report; Discussion; Acknowledgment; References; and when relevant Supporting Information. Video is welcome as Supporting Information.

(4) LETTER TO THE EDITOR

Word limit: 500 words.

Abstract: No abstract.

References: Maximum 4.

Figures/tables: Maximum 1 (Multi panel figures allowed).

Description: Letters may be submitted to the Editor on any topic of discussion; clinical observations as well as letters commenting on papers published in recent issues. Letter to the Editor are not subjected to peer-review. Submissions may be edited for length, grammatical correctness, and journal style. Authors will be asked to approve editorial changes that alter the substance or tone of a letter or response. Letters that offer perspective on content already published in the Journal can use an arbitrary title, but a Response from authors must cite the title of the first letter: e.g. Response to [title of Letter]. This ensures that readers can track the line of discussion.

(5) COMMENTARY

[BY INVITATION OR AFTER PROPOSAL OUTLINE]

Word limit: 1,500 words excluding references, tables and figures.

Title: 115 characters maximum including spaces.

References: Maximum 5.

Figures/tables: Maximum 1-2.

Description: Commentaries discuss a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field.

(6) MINI REVIEW

[BY INVITATION OR AFTER PROPOSAL OUTLINE]

Word limit: 3,000 words including abstract but excluding references, tables and figures.

Abstract: 250 words maximum, structured or unstructured.

References: Maximum 50.

Figures/tables: Minimum 1 image or figure.

Description: Mini reviews are comprehensive analyses of specific topics. They are submitted upon invitation by the Editor. Proposals for reviews may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.

(7) REVIEW

[BY INVITATION OR AFTER PROPOSAL OUTLINE]

Word limit: 5,000 words including abstract but excluding references, tables and figures.

Abstract: 250 words maximum, structured or unstructured.

References: No maximum.

Figures/tables: Minimum 2 images or figures.

Description: Reviews are comprehensive analyses of specific topics. They are submitted upon invitation by the Editor. Proposals for reviews may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.

(8) EDITORIAL

[BY INVITATION OR AFTER PROPOSAL OUTLINE]

Word Limit: 1,600 words.

Abstract: No abstract.

References: Maximum 5.

Description: Proposals for Editorials may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.

(9) GUIDELINE

Word limit: 5,000 words, or to be determined in consultation with Editors if longer.

Abstract: 250 words maximum, unstructured (no use of sub-headers).

References: No maximum.

Description: Guidelines designed to help clinicians make decisions about appropriate diagnosis and treatment for specific circumstances.

(10) SPECIAL REPORT

[BY INVITATION OR AFTER PROPOSAL OUTLINE]

Word limit: To be determined in consultation with Editors.

Preface: 250 words maximum, unstructured (no use of sub-headers).

References: No limit.

Description: Country, meeting or special subject reports. Proposals for these articles may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited articles will undergo peer review prior to acceptance.

(11) CLINICAL TRIAL

Word limit: 4,000 words, including title page, abstract but excluding references, tables and figures.

Abstract: 250 words maximum, structured (sub-headers): Introduction, Materials and Methods, Results, Discussion.

References: No limit.

Figures/tables: Maximum 5 (1a, 1b, 1c are counted as 3 figures not 1 figure). A flow diagram should be included.

Description: Full-length reports of preventive, therapeutic, or diagnostic intervention, and the follow up to determine the effect of the intervention. Arrange text as follows: Abstract; Introduction; Materials and Methods; Results; Discussion; Acknowledgment; References; and when relevant Supporting Information. If needed, authors may send an outline of the proposed paper for initial consideration. Trials should adhere to sections 6 and 7 of this author guide.

4. DISCLOSURE (contents)

Authors should declare any financial support or relationships that may pose conflict of interest in the Covering Letter and Acknowledgments.

5. ETHICAL CONSIDERATIONS (contents)

Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Edinburgh 2000), available at:

<http://www.wma.net/e/policy/b3.htm>. All investigations on human subjects must include a statement that the subject gave informed consent. Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used). In general, submission of a case report should be accompanied by the written consent of the subject (or parent/guardian) before pub-

lication; this is particularly important where photographs are to be used or in cases where the unique nature of the incident reported makes it possible for the patient to be identified. While the Editors recognize that it might not always be possible or appropriate to seek such consent, the onus will be on the authors to demonstrate that this exception applies in their case. Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research.

6. CLINICAL TRIALS REGISTRY (contents)

We strongly recommend, as a condition of consideration for publication, registration in a public trials registry. Trials register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we request registration by April 1, 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as studies on pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt.

We do not advocate one particular registry, but registration are with a registry that meets the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine (<http://www.clinicaltrials.gov>); (2) the International Standard Randomized Controlled Trial Number Registry (<http://www.controlled-trials.com>); (3) the Australian New Zealand Clinical Trials Registry (<http://www.anzctr.org.au>); (4) the Chinese Clinical Trials Register (<http://www.chictr.org>);

(5) the Clinical Trials Registry - India (<http://www.ctr.in>); and (6) University hospital Medical Information Network (UMIN) (<http://www.umin.ac.jp/ctr/>).

7. RANDOMIZED CONTROLLED TRIALS (contents)

Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement: <http://www.consort-statement.org>

8. COPYRIGHT (contents)

Papers accepted for publication in the Journal become copyright of the Asian Association for the Study of Diabetes and Wiley-Blackwell, and authors will be asked to sign a transfer of copyright form. In signing the transfer of copyright, it is assumed that authors have obtained permission to use any copyrighted or previously published material. All authors must read and agree to the conditions outlined in the Copyright Transfer Agreement, and must sign the Agreement. Acceptance of a manuscript is contingent upon receipt of a signed Copyright Transfer Agreement.

NIH Public Access Mandate For those interested in our policy on the NIH Public Access Mandate, please consult our policy statement: <http://www.wiley.com/WileyCDA/Section/id-321171.html>

9. STYLE OF MANUSCRIPTS (contents)

Manuscripts must follow the style detailed in the International Committee of Medical Journal Editors' revised 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication', as presented at: <http://www.ICMJE.org/>

Spelling The Journal uses US spelling and authors should therefore follow the latest edition of the *Merriam-Webster's Collegiate Dictionary*. Foreign names and terms, such as names of chemicals should be written in the original language. Proper nouns and German nouns should be capitalized.

Units All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poids et Mesures (BIPM) website at: <http://www.bipm.org/>

Abbreviations Must be used sparingly – only where they ease the reader's task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

Trade names Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

10. STRUCTURE OF MANUSCRIPTS (contents)

The length of manuscripts must adhere to the specifications under the section Manuscript Categories.

Manuscripts should be presented in the following order: (i) title page, (ii) abstract and keywords, (iii) text, (iv) acknowledgments including disclosure, (v) references, (vi) supporting information, (vii) figure legends, (viii) tables (each table complete with title and footnotes) and (ix) figures. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

TITLE PAGE

The title page should contain (i) manuscript category, (ii) the title of the paper, (iii) the full names of the authors, (iv) the names and addresses of the institutions at which the work was carried out, (v) the full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript should be sent (vi) short running title, and (vii) a word count.

The present address of any author, if different from that where the work was carried out, should be supplied in a footnote. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified. The title should be short, informative and contain the major key words so that readers and in particular online users will discover the article easily in online search. Do not use abbreviations in the title. A short running title (less than 40 characters including spaces) should also be provided. The running title is the short title in the upper right-hand corner of articles to help article search.

ABSTRACT AND KEYWORDS

The length of abstracts must adhere to the specifications under the section Manuscript Categories. Please note that the requirements differ between manuscript types. The abstract should not contain abbreviations or references.

Up to three keywords, for the purposes of indexing and peer review, should be supplied below the abstract, in alphabetical order, and

should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH): <http://www.nlm.nih.gov/mesh/meshhome.html>

TEXT

Please note that the requirements differ between manuscript types. Please refer to MANUSCRIPT CATEGORIES for individual requirements.

ACKNOWLEDGMENTS

The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors' industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Thanks to anonymous reviewers are not appropriate.

REFERENCES

The Vancouver system of referencing should be used (examples are given below). In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited in tables or figure legends, number according to the first identification of the table or figure in the text. In the reference list up to 3 authors; when four or more, list the first three followed by et al. Do not use *ibid.* or *op cit.* Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2000, unpublished data). All citations mentioned in the text, tables or figures must be listed in the reference list. Names of journals should be abbreviated in the style used in *Index Medicus*. Authors are responsible for the accuracy of the references.

Journal articles: Sculpher MJ, Buxton MJ, Ferguson BA et al. A relative cost-effectiveness analysis of different methods of screening for diabetic retinopathy. *Diabet Med* 1991; 8: 644-650.

Journal articles published ahead of issue (print or online): Benz PJ, Soll J, Bölter B. Protein transport in organelles: The composition, function and regulation of the Tic complex in chloroplast protein import. *FEBS Journal*, 2009. doi: 10.1111/j.1742-4658.2009.06874.x

Books: Pickup J, Williams G. *Textbook of Diabetes*, 2nd edn. Oxford: Blackwell Science 1997.

Chapters in edited books: Russell, W.E. & Van Wyk, J.J. Peptide growth factor. In *Endocrinology* (ed. L. J. De Groot). W. B. Saunders, Philadelphia, 1989: 2504-2524.

TABLES

Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for *P*-values. Statistical measures such as SD or SEM should be identified in the headings. Tables should be submitted in Microsoft Word or Excel. Image files and groupings of text boxes should be avoided. If tables have been reproduced from another source, a letter from the copyright holder (usually the Publisher), stating authorization to reproduce the material, must be attached to the covering letter.

FIGURES

All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated using a scale bar on the illustration. If figures have been reproduced from another source, a letter from the copyright holder (usually the Publisher), stating authorization to reproduce the material, must be attached to the covering letter.

Size: Figures sizes to fit within the column (82 mm), intermediate (118 mm) or the full text width (173 mm).

Resolution: Figures must be supplied as high resolution saved as .eps or .tif. Halftone figures 300 dpi (dots per inch), Color figures 300 dpi saved as CMYK, figures containing text 400 dpi, Line figures 1000 dpi.

Color figures: Files should be set up as CMYK (cyan, magenta, yellow, black) and not as RGB (red, green, blue) so that colors as they appear on screen will be a closer representation of how they will print in the Journal.

Line figures: Must be sharp, black and white graphs or diagrams, drawn professionally or with a computer graphics package.

Text sizing in figures: Lettering must be included and should be sized to be no larger than the journal text or 8 point (Should be readable after reduction – avoid large type or thick lines).

Line Width: Between 0.5 and 1 point.

Figure legends: Type figure legends on a separate page. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement. More help on preparation of illustrations can be found at: <http://authorservices.wiley.com/>

EQUATIONS

Equations should be numbered sequentially with Arabic numerals; these should be ranged right in parentheses. All variables should appear in italics. Use the simplest possible form for all mathematical symbols.

11. SUPPORTING INFORMATION (contents)

Supporting Information is provided by the authors to support the content of an article but they are not integral to that article. They are hosted via a link on Wiley Online Library but do not appear in the print version of the article. Supporting Information must be submitted together with the article for review; they should not be added at a later stage. They can be in the form of tables, figures, appendices and even **video footage**. Reference to Supporting Information in the main body of the article is allowed. However, it should be noted that excessive reference to a piece of Supporting Information may indicate that it would be better suited as a proper reference or fully included figure/table. The materials will be published as they are supplied and will not be checked or typeset in any way. All Supporting Information files should come with a legend, listed at the end of the main article. Each figure and table file should not be larger than 5MB, although video files may be larger. Prior to submission, please check the guidelines: <http://authorservices.wiley.com/>

12. SUBMISSION OF MANUSCRIPTS (contents)

Manuscripts must be submitted online at: <http://jdi.edmgr.com>
Authors must supply an email address as all correspondence will be by email.

WORD 2007

Authors must note that Word 2007 is not yet compatible with journal production systems. Unfortunately, the journal cannot accept Microsoft Word 2007 documents until such time as a stable production version is released. Please use Word's 'Save As' option therefore to save your document as an older (.doc) file type.

GENERAL

All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication.

- Submissions must be double-spaced.
- All margins should be at least 30 mm.
- All pages should be numbered consecutively in the top right-hand corner, beginning with the title page.
- Do not use 'Enter' at the end of lines within a paragraph.
- Turn the hyphenation option off; include only those hyphens that are essential to the meaning.
- Specify any special characters used to represent non-keyboard characters.
- Take care not to use l (ell) for 1 (one), O (capital o) for 0 (zero) or ß (German ess-zett) for β (Greek beta).
- Use a tab, not spaces, to separate data points in tables. If you use a table editor function, ensure that each data point is contained within a unique cell (i.e. do not use carriage returns within cells).
- Each figure should be supplied as a separate file, with the figure number incorporated in the file name. For submission, low-resolution figures saved as .jpg or .bmp files should be uploaded, for ease of transmission during the review process.

COVERING LETTER

Papers are accepted for publication in the Journal on the understanding that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. This must be stated in the covering letter.

The covering letter must also contain an acknowledgment that all authors have contributed significantly, and that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified.

Names of potential reviewers and of reviewers whom they would prefer not to review the manuscript will be mentioned if you have any.

Authors must also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions

of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). All investigations on human subjects must include a statement that the subject gave informed consent and patient anonymity should be preserved. Authors should declare any financial support or relationships that may pose conflict of interest.

13. PROOFS (contents)

Corresponding authors must supply an email address to which correspondence can be emailed while their article is in production. Notification of the URL from where to download a Portable Document Format (PDF) typeset page proof, associated forms and further instructions will be sent by email to the corresponding author. The purpose of the PDF proof is a final check of the layout, and of tables and figures. Alterations other than the *essential* correction of errors are unacceptable at PDF proof stage. The proof should be checked, and approval to publish the article should be emailed to the Publisher by the date indicated, otherwise, it may be signed off by the Editor or held over to the next issue. Acrobat Reader will be required in order to read the PDF. This software can be downloaded (free of charge) from the following Web site:

<http://www.adobe.com/products/acrobat/readstep2.html>. This will enable the file to be opened, read on screen, and printed out in order for any corrections to be added. Further instructions will be sent with the proof.

14. OFFPRINTS (contents)

A PDF offprint of the online published article will be provided free of charge to the corresponding author, and may be distributed subject to the Publisher's terms and conditions. A minimum of 50 paper offprints will be provided upon request, at the author's expense. These paper offprints may be ordered online. Please visit <http://offprint.cosprinters.com/>, fill in the necessary details and ensure that you type information in all of the required fields. If you have queries about offprints please email offprint@cosprinters.com

15. COLOR and PAGE FEES (contents)

There is no submission or page charges to an author.

Color figures are not charged for online publication. For print publication, a charge of A\$1100/US\$530/¥64,000 for the first three color figures and A\$550/US\$265/¥32,000 for each extra color figure thereafter will be charged to the author. (Prices in A\$ include GST.) The Editorial Office will decide if color printing is warranted, and if so a fee will be

charged to the author.

16. TRACKING MANUSCRIPTS (contents)

Author Services enables authors to track their article, once it has been accepted, through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production so they do not need to contact the Production Editor to check on progress. For more details on online production tracking and for a wealth of resources, including FAQs and tips on article preparation, submission and more: <http://authorservices.wiley.com/bauthor>

17. ONLINE OPEN (contents)

OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see <http://wileyonlinelibrary.com/onlineopen#OnlineOpenTerms>. Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: <https://wileyonlinelibrary.com/onlineopen>. Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

18. EARLYVIEW (contents)

EarlyView articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. *EarlyView* articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of *EarlyView* articles means that they do not yet have volume, issue or

page numbers, so *EarlyView* articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs: <http://www.doi.org/faq.html>

19. THE JOURNAL ONLINE ([contents](#))

For more information, visit the Journal home page:

<http://wileyonlinelibrary.com/journal/JDI>

Visit Wiley-Blackwell's web pages for general submission guidelines and digital graphics standards: <http://authorservices.wiley.com/>

20. EDITORIAL OFFICE ([contents](#))

JDI Editorial Office

c/o Wiley Japan

4F, Frontier Koishikawa Bldg.

1-28-1 Koishikawa, Bunkyo-ku

Tokyo 112-0002

Japan

Email: JDI@wiley.com

Tel: +81 3 3830 1220

Fax +81 3 5689 7278